G8 Dementia Summit

CONFERENCE 2013-12-11 00:00:00-2013-12-11 00:00:00 London, England 11 December 2013 0

Sheila Chervin

N/A
Larchmont, United States

PAPER Hunter C, Jankovic J

Double-blind, placebo-controlled study to assess safety and efficacy of riluzole as a neuroprotective drug in patients with early, untreated Parkinson's disease.

Neurology. 52 (Suppl. 2): 214-215, 12 Apr 1999. USA

PAPER Cudkowicz, Rosas, Hayden

Riluzole therapy in patients with Huntington's disease.

Neurology. 50 (Suppl. 4): 72, Apr 1998

A Sahal on ACP Journal Club. Donepezil or memantine improved cognitive functioning in moderate-to-severe Alzheimer disease.

COMMENT I recommend this paper. 0 Arwa.o

Steven Paul on Averting a Late-life Crisis: Midlife ApoE2 Clears Plaques in Mice

COMMENT The paper by Hudry et al. is a beautiful extension of a paper my lab published almost nine years ago using viral vectors to deliver ApoE isoforms to the brains of PDAPP mice (see Dodart et al., 2005). In our study we showed that direct intrahippocampal ad

Paul Coleman on More Evidence for AD Starting Without Brain Amyloid

COMMENT I suggest that the E693delta (Osaka) mutation in APP may be pertinent to the SNAP cases (e.g., Tomiyama et al., 2008; Shimada et al., 2011). Paul_Coleman 0 A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. Clinical cou

Takaomi Saido on The Arctic AβPP mutation leads to Alzheimer's disease pathology with highly variable topographic deposition of differentially truncated Aβ.

COMMENT To my knowledge, this is the first paper describing neuropathology of AD patients with Arctic mutation. 0 saido

Takaomi Saido on The off-rate of monomers dissociating from amyloid-β protofibrils.

COMMENT This is a very important study. What would the kinetics be if the authors used amyloid protofibrils and filbrils isolated from human brains? 0 saido

Jürgen Götz on Sustained peripheral depletion of amyloid-β with a novel form of neprilysin does not affect central levels of amyloid-β.

COMMENT A very elegant study done in mice, rats, and monkeys showing that clearance of Aβ from the brain is most likely not because of a sink effect between this organ and the periphery. 0 j.goetz

Jürgen Götz on Soluble pathological tau in the entorhinal cortex leads to presynaptic deficits in an early Alzheimer's disease model.

COMMENT This is an interesting paper that supports our findings in mouse models and cell lines that soluble tau is toxic, as evidenced by the trapping of the kinesin adapter protein JIP1 in the soma under conditions where tau levels (irrespective of a pathogenic

MAPT A227A

MUTATIONS MAPT 44073889 GRCh37/hg19 rs1052553 A G g.109929A> G g.107103A> G Exon 9 Point, Silent Coding Unknown. This variant segregates with the H2 haplotype, which may be associated with decreased tau levels in the brain. Not applicable. A227A Frontotempora

PAPER Gordon RY, Kapralova MV, Godukhin OV, Arkhipov VI

Memory Disorders in Rats after Impairment of the Dorsal Hippocampal CA3 Field with Kainic Acid.

Bull Exp Biol Med. 2013 Sep;155(6):805-8090. PubMed: 24288771

PAPER Molino I, Colucci L, Fasanaro AM, Traini E, Amenta F

Efficacy of memantine, donepezil, or their association in moderate-severe Alzheimer's disease: a review of clinical trials.

ScientificWorldJournal. 2013;2013:925702. Epub 2013 Oct 29 PubMed: 24288512

Kimberly S Leight

Huntington's patient
Raleigh, United States